medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2014, Number 2

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2014; 12 (2)

Cutaneous pseudoporphyria: Case report and literature review

Chaparro MDA, Pasos EA, Morales TML

Language: Spanish
References: 32
Page: 111-113
PDF size: 98.56 Kb.


ABSTRACT

A rare condition equally affecting any gender and age group, pseudoporphyria is characterized by painful blistering of sunexposed areas, with clinical/histological findings suggestive of porphyria cutanea tarda, but without its biochemical changes.
This article describes a patient with typical lesions and adequate therapeutic response, and reviews existing literature.


REFERENCES

  1. Green JJ, Manders S. “Pseudoporphyria”. J Am Acad Dermatol 2001; 44: 1-9.

  2. Crowson A, Magro C. “Recent advances in the pathology of cutaneous drug eruptions”. Dermatol Clin 1999; 17: 537-560.

  3. Phung T, Pipkin C, Tahan S, Chiy D. “b-lactam antibiotic-induced pseudoporphyria”. J. Am Acad Dermatol 2004; 51: 880-882.

  4. Rivers J, Barnetso R. “Naproxen-induced bullous photodermatitis”. Med J Aust 1989; 151: 167-168.

  5. Soto JA, Zárate MG, Campos JE, Hernández M. “Pseudoporfiria por naproxeno”. Dermatol Rev Mex 2012; 56(4): 258-261.

  6. Schmutz JL, Barbaud A, Thechot P. “Pseudoporphyria and coxib”. Ann Dermatol Venereol. 2006; 133(2): 213.

  7. O’Hagan A, Irvine A, Allen G. “Pseudoporphyria induced by mefenamic acid”. Br J Dermatol 1998; 139: 1131-1132.

  8. Breier F, Feldmann R, Pelzl M, Gschanait F. “Pseudoporphyria cutanea tarda induced by furosemide in a patient undergoing peritoneal dialysis”. Dermatology 1998; 197: 271-273.

  9. Dolan C, Hall M, Blazes D, Norwood C. “Pseudoporphyria as a result of voriconazole use: a case report”. Int J Dermatol 2004; 43: 768-771.

  10. Lenfetey A, Friedmann D, Burke WA. “Metformin-induced pseudoporphyria”. J Drugs Dermatol 2012; 11(11): 1272.

  11. Anon. “Drugs induced cutaneous photosensitivity: some drugs warrant routine precautions”. Prescrire Int 2000; 9(48): 117-122.

  12. Schad S, Kraus A, Haubitz I, Trcka J, Hamm H, Girscl H. “Early onset pauciarticular arthritis is the major risk factor for naproxen-induced pseudoporphyria in juvenile idiopathic arthritis”. Arthritis Res Ther 2007; 9(1); 10.

  13. O’Donogue NB, Higgins EM. “Case 1: Naproxen-induced pseudoporphyria”. Clin Exp Dermatol 2002; 27(4): 339-340.

  14. Schad SG, Hamm H, Girschick HJ. “Bullae, erosions and scars in the face of 2 girls with idiopathic arthritis. Naproxen-induced pseudoporphyria”. Der Hautarzt 2002; 53(1): 51-53.

  15. Lutzow-Holm C. “Naproxen-induced bullous photodermatitis (pseudoporphyria)”. Tidsskr Nor Laegeforen. 1991 Sep 20; 111(22): 2739-2740.

  16. De Silva B, Banney L, Uttley W, Lugmani R, Schofield O. “Pseudoporphyria and nonsteroidal antiinflammatory agenst in children with juvenile idiopathic arthritis”. Pediatr Dermatol. 2000; 17(6): 480-483.

  17. Schmutz JL, Barbaud A, Trechot P. “Flutamide and pseudoporphyria”. Ann Dermatol Venereol. 1999 Apr; 126(4): 374.

  18. Wilson CL, Mendelsohn SS. “Identical twins with sunbed-induced pseudoporphyria”. J R Soc Med 1992; 85: 45-46.

  19. Epstein JH. “Pseudoporphyria and UVA suntan salons”. Photochem Photobiol 1987; 45: 40S.

  20. Kochs C, Muhlenstadt E, Neumann NJ, Hanneken S. “Solarium-induced pseudoporphyriabb and variegate porphyria as rare differential diagnoses of porphyria cutanea tarda”. Der Hautarzt 2009 Oct; 60(10): 790-793.

  21. Vadoud-Seyedi J, de Dobbeleer G, Simonart T. “Treatment of hemodyalisis- associated pseudoporphyria with N-acetilcysteine: report of two cases”. Br J Dermatol 2000; 142: 580-581.

  22. Poh-Fitzpatrick MB, Bellet N, DeLeo VA, Grossmann ME, Bickers DR. “Porphyria cutanea tarda in two patients treated with hemodyalisis for chronic renal failure”. N Engl J Med 1978; 299: 292-294.

  23. Katolus, AC, Ferra D, Toumbis E, Papadavid E, Kanelleas A, Panayiotides I, Rigopoulos D. “Pseudoporphyria associated with nonhemodialyzed renal insuffiency, successfully treated with oral N-acetylcysteine”. Case Rep Dermatol Med. 2013.

  24. Azak A, Yenigun E, Kocak G, Huddam B, Kahve B. “Pseudoporphyria in a hemodialysis patient successfully treated with oral glutamine”. Hemodial Int. 2013 Jul; 17(3): 466-467.

  25. Khaled A, Souissi A, Fazaa B, Hawilo A, Kamoun MR. “Bullous dermatosis of hemodialysis: pseudoporphyria”. Tunis Med. 2011 Oct; 89(10): 799-800.

  26. Judd L. “Pseudoporphyria due to cola”. Int J Dermatol 1991; 30: 674-675.

  27. Kasuya A, Hashizume H, Hirakawa S, Tokura Y. “Hemodialysis-induced pseudoporphyria successfully treated with glutathione”. Eur J Dermatol 2012; 22(1): 137-138.

  28. Creemers MCW, Chang A, Franssen JHAM, Fiselier tjw, Van Riel PLCM. “Pseudoporphyria due to naproxen”. Scand J Rheumatol 1995; 24: 185-187.

  29. Fevang SA, Kroon S, Skadberg O. “Pseudoporphyria of porphyria cutanea tarda? Diagnostic and treatment difficulties”. Acta Derm Venereol. 2008; 88(4): 426-427.

  30. Maynard B, Peters MS. “Histologic and inmunofluorescence study of cutaneous porphyrias”. J Cutan Pathol 1992; 19: 40-47.

  31. Baker EJ, Reed KD, Dixon SL. “Chlorthalidone-induced pseudoporphyria: clinical and microscopic findings of a case”. J Am Acad Dermatol 1989; 21: 1026-1029.

  32. Mehta S, Lang B. “Long-term follow up of naproxen-induced pseudoporphyria in juvenile rheumatoid arthritis”. Artrhritis Rheum 1999; 126: 374.




2020     |     www.medigraphic.com